^
Association details:
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Checkmate 040 Cohort 5: long-term efficacy and safety of nivolumab in patients with ChildPugh B advanced hepatocellular carcinoma and associations between baseline biomarker analyses and outcomes

Published date:
06/26/2021
Excerpt:
Patients with CPB 7 or 8 aHCC (sorafenib naive n = 25; sorafenib treated n = 24) received nivolumab 240 mg intravenously for 30 minutes every 2 weeks...Lower tumor expression of PD-1 and CD163 was associated with longer OS (Fig)...